Xiao-Yin Zhang1, Graham P Collins2,3. 1. Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. 2. Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. graham.collins@ouh.nhs.uk. 3. Department of Haematology, Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK. graham.collins@ouh.nhs.uk.
Abstract
PURPOSE OF REVIEW: Checkpoint inhibitors (CPIs) targeting PD1 are highly active in relapsed/refractory classical Hodgkin lymphoma. A plethora of recent studies, often small and non-randomised, have raised many questions about how to optimally integrate these into clinical practice. We aim to discuss the use of CPIs in different relapsed/refractory settings in an effort to better define their role and highlight areas of research. RECENT FINDINGS: CPIs have shown efficacy at first relapse, as salvage pre- and post-autologous (ASCT) and allogeneic stem cell transplant (alloSCT) and as maintenance post-ASCT. Immune-related adverse events require careful attention, especially when used peri-alloSCT, where it is associated with hyperacute graft-versus-host disease. Newer PD1 inhibitors, as well as strategies to overcome CPI resistance, are being tested. CPIs are increasingly deployed at earlier points in the classical Hodgkin lymphoma pathway. Whilst progress is clearly being made, randomised studies are required to more clearly define the optimal positioning of these agents.
PURPOSE OF REVIEW: Checkpoint inhibitors (CPIs) targeting PD1 are highly active in relapsed/refractory classical Hodgkin lymphoma. A plethora of recent studies, often small and non-randomised, have raised many questions about how to optimally integrate these into clinical practice. We aim to discuss the use of CPIs in different relapsed/refractory settings in an effort to better define their role and highlight areas of research. RECENT FINDINGS: CPIs have shown efficacy at first relapse, as salvage pre- and post-autologous (ASCT) and allogeneic stem cell transplant (alloSCT) and as maintenance post-ASCT. Immune-related adverse events require careful attention, especially when used peri-alloSCT, where it is associated with hyperacute graft-versus-host disease. Newer PD1 inhibitors, as well as strategies to overcome CPI resistance, are being tested. CPIs are increasingly deployed at earlier points in the classical Hodgkin lymphoma pathway. Whilst progress is clearly being made, randomised studies are required to more clearly define the optimal positioning of these agents.
Authors: C Martínez; C Canals; B Sarina; E P Alessandrino; D Karakasis; A Pulsoni; S Sica; M Trneny; J A Snowden; E Kanfer; N Milpied; A Bosi; S Guidi; C A de Souza; R Willemze; R Arranz; L Jebavy; A Hellmann; D Sibon; R Oneto; J J Luan; P Dreger; L Castagna; A Sureda Journal: Ann Oncol Date: 2013-05-26 Impact factor: 32.976
Authors: Sally Arai; Michelle Fanale; Sven DeVos; Andreas Engert; Tim Illidge; Peter Borchmann; Anas Younes; Franck Morschhauser; Alex McMillan; Sandra J Horning Journal: Leuk Lymphoma Date: 2013-06-05
Authors: Craig H Moskowitz; Matt J Matasar; Andrew D Zelenetz; Stephen D Nimer; John Gerecitano; Paul Hamlin; Steven Horwitz; Alison J Moskowitz; Ariela Noy; Lia Palomba; Miguel-Angel Perales; Carol Portlock; David Straus; Jocelyn C Maragulia; Heiko Schoder; Joachim Yahalom Journal: Blood Date: 2011-12-19 Impact factor: 22.113
Authors: D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: Marc P E André; Théodore Girinsky; Massimo Federico; Oumédaly Reman; Catherine Fortpied; Manuel Gotti; Olivier Casasnovas; Pauline Brice; Richard van der Maazen; Alessandro Re; Véronique Edeline; Christophe Fermé; Gustaaf van Imhoff; Francesco Merli; Réda Bouabdallah; Catherine Sebban; Lena Specht; Aspasia Stamatoullas; Richard Delarue; Valeria Fiaccadori; Monica Bellei; Tiana Raveloarivahy; Annibale Versari; Martin Hutchings; Michel Meignan; John Raemaekers Journal: J Clin Oncol Date: 2017-03-14 Impact factor: 44.544
Authors: Stefanie Kreissl; Helen Goergen; Ina Buehnen; Carsten Kobe; Alden Moccia; Richard Greil; Dennis A Eichenauer; Josée M Zijlstra; Jana Markova; Julia Meissner; Michaela Feuring-Buske; Martin Soekler; Hans-Joachim Beck; Wolfgang Willenbacher; Wolf-Dieter Ludwig; Thomas Pabst; Max S Topp; Felicitas Hitz; Martin Bentz; Ulrich Bernd Keller; Dagmar Kühnhardt; Helmut Ostermann; Bernd Hertenstein; Walter Aulitzky; Georg Maschmeyer; Tom Vieler; Hans Eich; Christian Baues; Harald Stein; Michael Fuchs; Volker Diehl; Markus Dietlein; Andreas Engert; Peter Borchmann Journal: Lancet Haematol Date: 2021-06 Impact factor: 18.959
Authors: Peter Borchmann; Annette Plütschow; Carsten Kobe; Richard Greil; Julia Meissner; Max S Topp; Helmut Ostermann; Judith Dierlamm; Johannes Mohm; Julia Thiemer; Martin Sökler; Andrea Kerkhoff; Miriam Ahlborn; Teresa V Halbsguth; Sonja Martin; Ulrich Keller; Stefan Balabanov; Thomas Pabst; Martin Vogelhuber; Andreas Hüttmann; Martin Wilhelm; Josée M Zijlstra; Alden Moccia; Georg Kuhnert; Paul J Bröckelmann; Bastian von Tresckow; Michael Fuchs; Beate Klimm; Andreas Rosenwald; Hans Eich; Christian Baues; Simone Marnitz; Michael Hallek; Volker Diehl; Markus Dietlein; Andreas Engert Journal: Lancet Oncol Date: 2021-02 Impact factor: 41.316